Menu

Search

  |   Business

Menu

  |   Business

Search

Neos Therapeutics to Present at the Cowen & Co. Annual Health Care Conference

DALLAS and FORT WORTH, Texas, March 05, 2018 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies, today announced that Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics, will present a company overview at the upcoming Cowen & Co. 38th Annual Health Care Conference on Monday, March 12, 2018 at 1:30 p.m. ET in Boston, MA.

A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.

About Neos Therapeutics

Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release  technology platform. Additional information about Neos is available at www.neostx.com.


CONTACTS:

Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
[email protected]

Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
[email protected]

Primary Logo

  • Market Data
Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.